Tongling Jieya Biotechnology has returned to profit in 2025 after three years of declining performance. The company reported revenue of RMB 772 million, or about $111 million, up 41.02% year on year, while net profit rose 296.97% to RMB 77.3 million, or about $11.1 million, according to its annual report.
Overseas Demand Drives the Rebound
Jieya’s overseas revenue climbed to RMB 520 million, or about $74.9 million, up 99% year on year, while domestic revenue fell 11.84% to RMB 252 million, or about $36.3 million. The results suggest the company’s recovery was driven far more by external demand than by growth in China.
The company mainly operates under OEM and ODM models, producing wet wipes and facial mask products for companies including Procter & Gamble and Johnson & Johnson, while also selling a limited number of self-owned brand products.
Masks and Personal Care Gain Speed
By category, wet wipe revenue reached RMB 675 million, or about $97.3 million, up 36.28%. Facial mask revenue rose 79.45% to RMB 73.8 million, or about $10.6 million, while personal care products climbed 381.92% to RMB 13.9 million, or about $2.0 million.
Jieya said it is accelerating a shift from traditional contract manufacturing toward a more professional ODM supply chain model. For Dewsia readers, the significance is that beauty-adjacent manufacturers are still finding growth where export exposure, category breadth, and supply-chain capability are strong enough to offset weaker domestic conditions.
